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92 The Journal of Thoracic and Cardioe are grateful to the editors of the Journal for allowing us to respond to
the editorial by Di Donato and colleagues.1
We wish to acknowledge the pioneering work by Drs Di Donato, Sabatier, and
ericanti and in particular Dr Dor in the field of surgery for patients with heart
ailure.
Their editorial raises several important issues. At the heart of the debate is
hether left ventricular reconstruction is proarrhythmogenic, antiarrhythmogenic,
r completely neutral. Dr Di Donato and colleagues have the largest collection of
atients who have undergone volume reduction surgery, and they have produced
any sentinel articles in this field.
The differences in outcomes can be explained by several factors. In our cohort
atients were at a more advanced stage of disease, with mean left ventricular
jection fractions of 22% compared with a median of 29% in Di Donato’s 2
e agree that major differences in arrhythmia occurrence could reflect the use of
ndocardial resection with cryoablation in the Dor series, and as noted, cryoablation
as performed in a minority of our patients. However, the patients referred to in our
tudy underwent surgical intervention as part of a comprehensive approach to the
anagement of their heart failure syndrome. They were not referred primarily for
neurysmectomy on the basis of arrhythmia, an indication that led to left
entricular reconstructive surgery in a significant number of this group’s se3
he arrhythmia management was based on electrophysiologic testing or im-
lantable cardioverter defibrillator implantation, with the latter approach well
upported by several recent studies showing the efficacy of implantable cardio-
erter defibrillators in the primary prevention of sudden death in patients with
schemic heart disease.
We do not perform electrophysiological studies routinely preoperatively be-
ause we support the hypothesis that revascularization and improved left ven-
ricular geometry with reduced wall stress should act to reduce the substrate for
rrhythmia. Thus apart from a research perspective, there appears to be no
otential benefit from preoperative studies. The differences in postoperative
nducibility might well be related to our lower use of endocardial resection and
ryoablation. We also agree that the use of a maximum of 2 extrastimuli during
rogrammed stimulation would be less sensitive in inducing ventricular arrhyth-
ias than our usual stimulation protocol of up to 3 extrastimuli at 2 right
entricular sites. We have also used a protocol with 4 extrastimuli, which has
een reported to yield equivalent inducibility rates to those of conventional
rotocols with 3 extrastimuli.4
We do not use amiodarone routinely as performed in the authors’ practice. The
se of amiodarone for the primary prevention of arrhythmias is of questionable
enefit, particularly in light of the SCD HeFT II study, which showed increased
ortality with amiodarone compared with placebo, albeit in a different patient
opulation from that described here.5
We acknowledge that left ventricular volumes would be very telling in assessing
utcome, but we did not have sufficient magnetic resonance imaging data to address
his, and patients with devices did not undergo magnetic resonance imaging.
In summary, our data indicate that patients with severe heart failure who undergo
eft ventricular reconstruction remain at high risk of malignant ventricular arrhyth-
ias. We cannot nor did we conclude that the risk was higher than preoperatively.
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Le believe that the difference in ventricular arrhythmias
an be explained by the patient profile, specifically that our
atients had more advanced disease with poorer left ven-
ricular ejection fractions. We would make a case for the
udicious use of adjunctive device therapy in patients un-
ergoing left ventricular reconstruction. Only a small per-
entage of our patients had an improvement in left ventric-
lar ejection fraction above the MADIT II cutoff of 36
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